Description: Bernard Zovighian: Thank you, Mark and welcome everyone. This strong Q3 results represent another quarter of double-digit sales growth. Sales in the quarter grew 12.6% to $1.55 billion driven by our comprehensive portfolio across multiple therapeutic areas, aortic, pulmonic, mitral and tricuspid as well and -- as well as an established presence in countries around the world.

Description: If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...

Description: Underscoring India's rising influence in global cardiovascular innovation, Meril Life Sciences presented the one-year outcomes from the pivotal LANDMARK Randomized Controlled Trial (RCT) during the Late-Breaking Trial sessions at PCR London Valves 2025, one of the world's most respected structural heart conferences. This milestone marks a significant moment for Indian MedTech, as the indigenous, balloon-expandable Myval THV series is directly compared with leading international transcatheter val

Description: Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.

Description: As global markets grapple with a range of challenges, including a record U.S. federal government shutdown and declining consumer sentiment, small-cap stocks have been under particular scrutiny amid these turbulent conditions. With the S&P 600 for small-cap stocks experiencing fluctuations, investors are increasingly looking at companies where insider buying may indicate confidence in long-term prospects despite broader market uncertainties. In such an environment, identifying stocks that show...

Description: Although Edwards Lifesciences has outpaced the broader market over the past year, analysts remain measured in their expectations, maintaining a cautiously optimistic view as they look for continued execution and sustained growth drivers.

Description: Edwards Lifesciences (EW) shares have drawn fresh attention as heightened implied volatility in the options market coincides with upgraded earnings estimates and increased full-year sales growth guidance. This signals increased anticipation ahead of upcoming earnings. See our latest analysis for Edwards Lifesciences. Edwards Lifesciences has enjoyed a solid stretch, with a 13.71% one-month share price return and a 15.83% gain year-to-date, further buoyed by upbeat earnings, a CFO transition...

Description: NEW ORLEANS, November 09, 2025--Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many driven by delayed diagnosis or treatment.

Description: JPMorgan Chase, Salesforce and Arista Networks headline new analyst reports highlighting growth drivers, cost pressures and competitive dynamics.

Description: Investors need to pay close attention to EW stock based on the movements in the options market lately.

Description: Investors need to pay close attention to EW stock based on the movements in the options market lately.

Description: In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above $60 per barrel while precious metals are stronger for the 3rd day in a row – Gold is above $4,040 and Silver is approaching $49 per ounce. A strong slate of quarterly Tech results are helping stock futures restore positive sentiment in the segment that was wounded on Thursday by more dubious results o

Description: Edwards Lifesciences stock fell Friday, though the medtech company boosted its 2025 outlook after beating quarterly calls.

Description: Ullem, who has held the position for more than a decade, will transition to an advisory role after his replacement is named by mid-2026.

Description: Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.

Description: Edwards Lifesciences Q3 earnings and sales beat estimates on robust TAVR and TMTT growth, though margins take a sharp hit.

Description: Edwards Q3 2025 revenues grew to $1.55bn, reflecting an uplift of 14.7% from around $1.35bn in Q3 2024.

Description: Edwards Lifesciences Corp (EW) reports a 12.6% revenue increase and raises full-year sales and EPS guidance, showcasing robust performance across therapeutic areas.

Description: Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly calls.

Description: IRVINE, Calif., October 30, 2025--Edwards Lifesciences (NYSE: EW) today announced that Scott Ullem, the company’s chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role.

Description: IRVINE, Calif., October 30, 2025--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025.

Description: In recent days, Edwards Lifesciences announced positive long-term clinical trial results for its SAPIEN TAVR technology and successful patient outcomes from real-world data on the SAPIEN M3 and EVOQUE valve systems at the annual TCT symposium. These data highlighted superior valve performance, durability, and quality-of-life improvements for patients with mitral and tricuspid valve disease, supporting Edwards’ leadership in structural heart therapies. The simultaneous presentation of...

Description: Edwards Lifesciences has seen its consensus analyst price target inch higher, rising from $87.73 to $88.83 as market sentiment improves. This slight increase is supported by a mix of optimism and caution in recent analyst commentaries, driven by promising clinical data and evolving market expectations. Stay tuned to learn how you can stay ahead of shifts in the Edwards Lifesciences narrative as new information becomes available. What Wall Street Has Been Saying 🐂 Bullish Takeaways Jefferies...

Description: Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls

Description: Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Description: SAN FRANCISCO, October 27, 2025--Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement

Description: SAN FRANCISCO, October 27, 2025--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards’ leadership in setting the standard for lasting valve performance and excellent patien

Description: Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Card

Description: Edwards Lifesciences (EW) shares have experienced movement recently, drawing interest from investors tracking shifts in the medical device sector. The company’s recent performance presents a useful opportunity to revisit its fundamentals, market position, and potential outlook. See our latest analysis for Edwards Lifesciences. After some recent ups and downs, Edwards Lifesciences’ share price has advanced 4.84% year-to-date. The one-year total shareholder return is 9.69%. While short-term...

Description: Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.

Description: RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.

Description: IRVINE, Calif., October 23, 2025--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Description: The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow

Description: Edwards Lifesciences Corporation (NYSE:EW) ranks among the best medical device stocks to invest in. Piper Sandler maintained its Overweight rating and $90 price target for Edwards Lifesciences Corporation (NYSE:EW) on October 7, ahead of the expected 7-year findings from Edwards’ PARTNER 3 study, which is set to be presented on October 27 at the Transcatheter […]

Description: West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.

Description: Strong TAVR demand and expanding valve therapies are set to power EW's Q3 results despite lower EPS estimates.